IPO - Profile

Summary

We are a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We focus our discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. In particular, we focus on “clinically proven” kinase targets, or those for which therapies have been developed by others to target those kinases, and that such drugs have demonstrated sufficient clinical efficacy and safety data to be approved by the United States Food and Drug Administration, More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 9,800,000 Positive High 23.9%

Offering Team

  • Legal counsel
  • Goodwin Procter LLP
  • Auditors
  • KPMG LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 28 Jul, 2021

Offer 29 Jul, 2021

Look Ahead

Lock Up Expiry Jan 29, 2022

IPO Terms

Offer Price $17.00
Offer Size 9M

Market Sentiments

Stock Price